Leuko, an MIT startup developing a solution that enables at-home noninvasive white blood cell (WBC) monitoring, announced a first closing of $5m for their Series A round.
The new funding came HTH VC, Good Growth Capital, IAG Capital Partners, Nina Capital, and angel investors.
The company intends to use the funds to accelerate clinical trials to obtain regulatory approval in collaboration with cancer centers, including Boston Medical Center and MD Anderson in the USA, and Dexeus and Hospital 12 de Octubre in Europe, and continue to pursue its go-to-market and partnership activities with healthcare providers, medical device distributors and pharmaceutical companies.
Founded by Carlos Castro-Gonzalez, Ian Butterworth, Aurelien Bourquard, and Alvaro Sanchez-Ferro, Leuko enables patients to place their finger onto an internet connected PointCheckTM device for 1 minute a day. The device measures WBC levels without a blood sample draw. The data is sent to the patient’s care team, which can triage findings to help patients receive appropriate, preventive treatments under the direction of their clinician.
FinSMEs
23/09/2022